In vivo testing of 177Lu-labelled anti-PSMA antibody as a new radioimmunotherapeutic agent against prostate cancer.
In Vivo 25(1):55-9 (2011) PMID 21282735
The goal of the present study was to test the (177)Lu-labelled anti-PSMA monoclonal antibody 3/F11 ((177)Lu-DOTA-3/F11) as a new radioimmunotherapeutic agent in a prostate cancer SCID mouse xenograft model.
Version: za2963e q8za9 q8zbc q8zcf q8zd3 q8ze3 q8zfc q8zgc